Mode
Text Size
Log in / Sign up

Ensitrelvir improves viral clearance and reduces viral RNA in patients with mild-to-moderate COVID-19Ensitrelvir helps clear the virus in mild to moderate COVID-19

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Note that Ensitrelvir significantly improves viral clearance and reduces RNA levels in mild-to-moderate COVID-19 cases.

This meta-analysis evaluated the efficacy of Ensitrelvir in patients with mild-to-moderate COVID-19 across a sample size of 2,890. The analysis compared Ensitrelvir at doses of 125 mg and 250 mg against a placebo to determine impacts on viral clearance and viral RNA levels.

Key findings indicate that both the 125 mg (MD = -37.74; P < 0.00001) and 250 mg (MD = -35.02; P < 0.00001) doses significantly improved viral clearance compared to placebo. Additionally, both dosages resulted in greater reductions in viral RNA (125 mg: MD = -1.41; 250 mg: MD = -1.37; both P < 0.00001). The proportion of patients maintaining a positive viral titer was significantly lower in the 125 mg group (RR 0.08; P < 0.00001) and the 250 mg group (RR 0.10; P < 0.00001). No significant differences were observed between the 125 mg and 250 mg dosage groups.

The authors note a need for further large-scale, variant-inclusive studies to validate and extend these findings. Clinical evidence supports the potential inclusion of Ensitrelvir in outpatient treatment protocols for patients with mild-to-moderate or asymptomatic COVID-19 infections.

When you catch a case of COVID-19, one of the biggest hurdles is getting the virus out of your body. New data suggests that a medication called Ensitrelvir may help speed up this process for people with mild to moderate cases of the illness.

Researchers looked at 2,890 patients and found that both the 125 mg and 250 mg doses of Ensitrelvir led to higher rates of viral clearance. This means the medicine helped the body clear the virus more effectively than a placebo. The study also showed significant reductions in viral RNA, which is the genetic material of the virus.

While these results are promising for outpatient treatment, there are still pieces of the puzzle missing. Because this was a meta-analysis, we need more large-scale studies that include different variants to fully confirm how well it works across all types of COVID-19. Talk to your doctor about how these findings might fit into your specific care plan.

What this means for you:
Ensitrelvir helps patients with mild to moderate COVID-19 clear the virus from their bodies faster.

Common questions

How does Ensitrelvir work for COVID-19?

Ensitrelvir helps patients with mild to moderate COVID-19 clear the virus from their systems. The study found that both 125 mg and 250 mg doses led to higher viral clearance and a significant reduction in viral RNA compared to a placebo.

Is there a difference between the 125 mg and 250 mg doses?

The study found no significant differences in the reported outcomes between the 125 mg and 250 mg dosage groups. Both doses were effective at improving viral clearance and reducing the amount of viral RNA in patients.

Is this treatment safe for mild cases?

The study suggests Ensitrelvir could be part of outpatient treatment for mild to moderate COVID-19. However, specific safety data like adverse events were not reported in this analysis. You should consult your doctor to discuss the best treatment for your specific health needs.

Study Details

Study typeMeta analysis
Sample sizen = 19
EvidenceLevel 1
PublishedJun 2026
View Original Abstract ↓
BACKGROUND: Coronavirus Disease (COVID-19), which is caused by SARS-CoV-2 virus, led to a worldwide pandemic in late 2019, thus challenged the healthcare infrastructure across the world, creating an urgent need for the development of effective antiviral medications to handle its spread and evolving strains. OBJECTIVE: This Meta-Analysis aims to investigate the overall efficacy and safety of Ensitrelvir. METHODS: We conducted a systematic review and meta-analysis, according to PRISMA guidelines, searching web databases for relevant literature. We limited our eligibility to randomized clinical trials involving mild-to-moderate COVID-19 patients. RESULTS: Our study included four randomized controlled trials involving a total of 2,890 patients. For patients with mild-to-moderate Covid-19, treatment with Ensitrelvir (125 mg or 250 mg) was associated with significantly improved outcomes compared to placebo across several metrics: higher viral clearance was observed for 125 mg [MD = - 37.74, P < 0.00001] and 250 mg [MD = - 35.02, P < 0.00001]; greater reductions in viral RNA were achieved by 125 mg [MD = -1.41, P < 0.00001] and 250 mg [MD = -1.37, P < 0.00001]; and a significantly lower proportion of patients maintained a positive viral titer at 125 mg [RR 0.08, P < 0.00001, I = 82%] and 250 mg [RR 0.10, P < 0.00001, I = 16%]. Ultimately, there were no significant differences in reported outcomes between the 125 mg and 250 mg Ensitrelvir dosage groups. CONCLUSION: This systematic review and meta-analysis support Ensitrelvir efficacy and safety in promoting rapid viral clearance and greater reduction in viral RNA in mild-to-moderate or asymptomatic COVID-19 patients, justifying its integration into outpatient treatment protocols while emphasizing the need for further large-scale, variant-inclusive studies to validate and extend these findings. REGISTRATION: PROSPERO (CRD420251030953).
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.